BioWorld Asia

Jan. 7, 2009

Genmab Shares Slide on Interim Zalutumumab Data

Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International) Read More

UK/U.S. Program Mapping Chemo Response to Cancers

Hair Loss Gene has Serendipitous Message for Genetic Sleuths

UK's Stem Cell Proponents Meeting to Discuss Future

Small EU Biofirms Benefit from Special Assistance

Cytos Shares Surge on Pfizer Deal Commitment

Cellectis Terminates genOway's Homologous Recombination Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026